MRC1 and colorectal carcinoma: The lack of suitable biomarkers for predictability of the efficacy of immune checkpoint therapy is a major setback since 12% to 40% of all MMR deficient metastatic CRC patients show resistance, including acquired resistance in patients that were sensitive to the therapy initially [105].